Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension

NCT02480517 | Unknown DMC

• 1 other identifier: KM14-003
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

The Wave VI study is a, multicenter, prospective, double-blind, randomized, sham controlled feasibility study of the safety of renal denervation in patients with stage I and II hypertension who have an average office systolic blood pressure between 150 and 180 mmHg and have not been on any antihypertensive medications for at least six months.

Conditions

Hypertension

Keywords

Hypertension; Renal Denervation

Outcome Measures

Primary Outcomes (2)

• Safety will be assessed by incidence of Major Adverse Events (MAE), defined as a composite of the following events:

  * All cause mortality; * End-stage Renal Disease defined as eGFR \< 15 ml/min or need for renal replacement therapy * Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications as assessed by toxicological and other medical analyses and testing. OR \- New renal artery stenosis \> 70% confirmed by angiography within 3 months of randomization

  3 months follow-up

• Change in Office Systolic Blood Pressure (OBP) as measured from screening visit one to the 3 months post randomization follow-up visit.

  Baseline and 3 months

Study Arms (2)

Investigational Therapy (Surround Sound)

EXPERIMENTAL

Investigational Therapy using external focused ultrasound

Device: Ultrasound

Sham Control

SHAM COMPARATOR

Blinded Sham Control Arm

Device: Sham Ultrasound

Interventions

Ultrasound DEVICE

Also known as: Surround Sound

Investigational Therapy (Surround Sound)

Sham Ultrasound DEVICE

Sham Control

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is at least 18 years of age and no more than 80 years of age and can be safely removed from present antihypertensive therapy.
• Subject has not been taking any anti-hypertensive medications for at least 6 months prior to study enrollment.
• Subjects must have an average office seated systolic BP (SBP) between 150 mmHg and 180 mmHg inclusive in the untreated state for a minimum of 2 weeks.
• Mean daytime ambulatory SBP \> 135 mmHg and no more than 170 mmHg in addition to mean daytime ambulatory DBP \> 85 mmHg.
• Subject has two functioning kidneys.
• Subject has an eGFR value of ≥ 30 ml/min/1.73 m² (MDRD formula).

You may not qualify if:

• a.Any known secondary causes of hypertension.
• b.Evidence of current or past history of any clinically significant renal artery stenosis on duplex ultrasound as defined by a finding of at least one of the following:
• Peak systolic velocity (PSV) in the main renal artery of 150 cm/s or greater;
• Renal/aortic ratio (RAR) of greater than 3.5; or
• Complete lack of Doppler signal in any portion of the main renal artery (signifying complete occlusion).
• c.Previously documented finding of a 30% or greater renal artery stenosis in any renal arterial vessels as determined by angiographic examination, MRA or CTA.
• d.Kidney stones that are 1 cm or greater in size, or that are symptomatic. e.History of intra-abdominal surgery within the past six months or surgery through retroperitoneal path at any time .
• f.Previous renal denervation g.Previous renal transplant. h.Heterogeneities in kidney morphology, such as large cysts or tumors (\> 2 cm), which are determined at discretion of the investigator to potentially interfere with treatment.
• i.Hemodynamically unstable valvular heart disease for which BP reduction would be hazardous in the judgment of the site investigator-physician.
• j.Documented history of severe orthostatic hypotension that requires treatment or has necessitated hospitalization.
• k.Primary pulmonary hypertension l.History of myocardial infarction, unstable angina pectoris, or cerebrovascular accident within the last six months.
• m.BMI over 35 kg/m² and/or mid-arm circumference \> 45 cm (creates difficulty with ABPM measurements) n.Anatomy that precludes treatment as determined by the Surround Sound System. This may include any of the following:
• Target treatment depth as measured by the Surround Sound System of greater than 13 cm (Skin to target);
• Lack of visualization of the renal artery and or renal artery Doppler signal with the Surround Sound System;
• Lack of visualization of the renal parenchyma due to obscuration by bowel or other abdominal or retroperitoneal structures; or

Sponsors & Collaborators

• Kona Medical Inc.: lead

MeSH Terms

Conditions

Hypertension

Interventions

Ultrasonography

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis

Central Study Contacts

Omar Dawood

CONTACT

odawood@konamedical.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 21, 2015
• First Posted: June 24, 2015
• Study Start: September 1, 2016
• Primary Completion: March 1, 2017
• Study Completion: December 1, 2017
• Last Updated: January 8, 2016

Record last verified: 2016-01